PMID: 11313093Apr 21, 2001Paper

Predictors of response to lithium augmentation in tricyclic antidepressant-resistant depression

Journal of Affective Disorders
T BschorM Bauer

Abstract

The efficacy of lithium augmentation in therapy-resistant depression has been shown in a series of well-designed, placebo-controlled studies. However, little is known about the predictors of a good response to this treatment strategy. We retrospectively examined the predictive value of 20 demographic, clinical, biochemical and endocrinological variables using a two-step logistic regression. Seventy-one in-patients with depression refractory to tricyclic antidepressants had received lithium augmentation as part of a standardised treatment protocol. Within 4 weeks 37 patients (52%) responded to lithium augmentation. Five variables with predictive value were found. Responders were more severely depressed according to the Bech-Rafaelsen Melancholia Scale. The duration of their index episode was shorter. Triiodothyronine serum levels were lower and neuroleptic co-medication and co-diagnosis of personality disorder were less frequent. This was an open, retrospective study. Severity of depression is a predictor of response to lithium augmentation. This result conflicts with recent studies but is similar to results found in studies of other pharmacological antidepressant strategies.

References

May 1, 1979·Comprehensive Psychiatry·H Helmchen
Jun 1, 1992·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·J Rybakowski, K Matkowski
Nov 1, 1986·The American Journal of Psychiatry·L H PriceG R Heninger
Jan 1, 1986·Journal of Psychiatric Research·W Maier, M Philipp
Jan 1, 1995·The British Journal of Psychiatry : the Journal of Mental Science·C L KatonaM M Robertson
Jun 1, 1994·International Clinical Psychopharmacology·C de Montigny
Nov 1, 1993·The British Journal of Psychiatry : the Journal of Mental Science·R T JoffeW Singer
Jan 1, 1995·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·C L Katona
Feb 1, 1997·Journal of Affective Disorders·E AlvarezR Noguera
Jul 14, 1999·Journal of Affective Disorders·M Smolka, R D Stieglitz
Oct 3, 1999·Journal of Clinical Psychopharmacology·M Bauer, S Dopfmer
Feb 1, 1960·Journal of Neurology, Neurosurgery, and Psychiatry·M HAMILTON

❮ Previous
Next ❯

Citations

May 1, 2001·Yeast·C CompagnoD Porro
Apr 27, 2007·Der Nervenarzt·T BschorM Bauer
Nov 13, 2003·European Psychiatry : the Journal of the Association of European Psychiatrists·G BertschyL Roth
Apr 23, 2003·Biological Psychiatry·Maurizio Fava
Aug 30, 2008·Schizophrenia Bulletin·Maria J Arranz, Shitij Kapur
Mar 5, 2014·CNS Drugs·Michael BauerMaximilian Pilhatsch
Nov 22, 2013·Journal of Personality Disorders·Giles Newton-HowesRobert Schoevers
Sep 15, 2010·Journal of Affective Disorders·Takeshi InoueTsukasa Koyama
Apr 19, 2012·Depression and Anxiety·Gebra Cuyún CarterLauren B Marangell
Sep 26, 2006·Journal of Affective Disorders·Christoph MulertOliver Pogarell
Jul 4, 2006·Journal of Affective Disorders·B ShapiraR H Belmaker
Mar 24, 2006·Journal of Psychiatric Research·Eva-Lotta BrakemeierMalek Bajbouj
Jun 5, 2003·The Psychiatric Clinics of North America·Roy H PerlisPerry F Renshaw
Jun 5, 2003·The Psychiatric Clinics of North America·Karin Esposito, Paul Goodnick
Jul 25, 2013·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Michael BauerUNKNOWN World Federation of Societies of Biological Psychiatry. Task Force on Unipolar Depressive Disorders
Jan 22, 2010·Journal of Affective Disorders·Hiroko SugawaraJun Ishigooka
Jan 1, 2004·International Journal of Psychiatry in Clinical Practice·Seetal Dodd, Michael Berk
Jul 2, 2005·Journal of Psychiatric Practice·S N GhaemiF K Goodwin
Mar 20, 2008·Psychiatric Genetics·Thomas J StammMichael Bauer
Jun 13, 2015·Journal of Clinical Psychopharmacology·JeanFrançois Costemale-LacosteFayçal Mouaffak
Jul 6, 2019·The Journal of Chemical Physics·Bholanath MaityLuigi Cavallo
Apr 3, 2002·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·S Nassir GhaemiFrederick K Goodwin
Feb 25, 2003·International Clinical Psychopharmacology·Rafael StryjerAbraham Weizman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here